Abstract: A method of inhibiting complement activity in a subject, the method comprising administering a soluble complement receptor type 1 (sCR1) variant to the subject.

Abstract: The present invention provides a method of treating cancer in a subject wherein the cancer comprises mutated KRAS or BRAF genes. The method comprises administering to the subject an effective amount of an antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof competes with SC104 for binding to the human colon cancer cell line Colo205.

Abstract: The present invention provides a method of treating cancer in a subject wherein the cancer comprises mutated KRAS or BRAF genes. The method comprises administering to the subject an effective amount of an antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof competes with SC104 for binding to the human colon cancer cell line Colo205.

Abstract: Human IGSF9 and LIV-1 polypeptides and DNA (RNA) encoding such polypeptides are disclosed. The disclosed polypeptides and/or polynucleotide are particularly useful generating antibodies, both modified and native, which bind IGSF9 or LIV-1. Also disclosed are pharmaceutical compositions and vaccines comprising the antibodies, polypeptides and polynucleotides of the invention. Also disclosed are methods for utilizing such polypeptides for identifying ligands, antagonists and agonists to said polypeptides. Finally, methods comprising the above-mentioned compositions are disclosed for the treatment, diagnosis, and/or prognosis of neoplastic disorders.

Abstract: The present invention is directed to novel methods of treating, indentifying or diagnosing a hyperproliferative disorder in a patient in need thereof. The methods of the invention include administering to a patient a composition comprising a binding molecule which binds to a cell surface expressed glycoprotein expressed predominantly in tumor or tumor-associated cells. In particular, the therapeutic and diagnostic methods of the present invention include the use of a binding molecule, for example an antibody or immunospecific fragment thereof, which specifically binds to a lung tumor-associated polypeptide, variant polypeptide or fragment thereof.

Abstract: The storage system is a suspended storage system in which one or more uprights are hung from a crossbar (24) and storage elements such as shelves or cabinets are attached to the uprights (1). Each of the uprights (1) is attached to the crossbar (24) by means of a coupling hook (25) which is removably attached to the end of the upright (1) and removably engages with the crossbar (24). The coupling hook (25) has a hook body (26) with a pair of L-shaped hooks (34) for engagement in the slots in the upright (1) and a grub screw (33) arranged to engage with the interior wall of the upright (1) so as to prevent relative movement of the coupling hook (25) with respect to the upright (1) when attached thereto. With this arrangement of the coupling hook (25), attachment to and removal of the coupling hook (25) from the crossbar (24) does not result in consequential loosening of the attachment of the coupling hook (25) to the upright (1).

Abstract: Human IGSF9 and LIV-1 polypeptides and DNA (RNA) encoding such polypeptides are disclosed. The disclosed polypeptides and/or polynucleotide are particularly useful generating antibodies, both modified and native, which bind IGSF9 or LIV-1. Also disclosed are pharmaceutical compositions and vaccines comprising the antibodies, polypeptides and polynucleotides of the invention. Also disclosed are methods for utilizing such polypeptides for identifying ligands, antagonists and agonists to said polypeptides. Finally, methods comprising the above-mentioned compositions are disclosed for the treatment, diagnosis, and/or prognosis of neoplastic disorders.

Abstract: The storage system is a suspended storage system in which one or more uprights are hung from a crossbar (24) and storage elements such as shelves or cabinets are attached to the uprights (1). Each of the uprights (1) is attached to the crossbar (24) by means of a coupling hook (25) which is removeably attached to the end of the upright (1) and removeably engages with the crossbar (24). The coupling hook (25) has a hook body (26) with a pair of L-shaped hooks (34) for engagement in the slots in the upright (1) and a grub screw (33) arranged to engage with the interior wall of the upright (1) so as to prevent relative movement of the coupling hook (25) with respect to the upright (1) when attached thereto. With this arrangement of the coupling hook (25), attachment to and removal of the coupling hook (25) from the crossbar (24) does not result in consequential loosening of the attachment of the coupling hook (25) to the upright (1).